github link
Accession IconERP023007

RNASeq and ChIPSeq: Therapeutic Targeting of the CBP/P300 Bromodomain for the Treatment of Castration Resistant Prostate Cancer

Organism Icon Homo sapiens
Sample Icon 45 Downloadable Samples
Technology Badge IconIllumina HiSeq 2500

Submitter Supplied Information

Prostate cancer is a leading cause of cancer death in men. While patients initially respond well to anti-androgen therapies, resistance is common. Here we identify a requirement for the transcriptional co-activators CBP/P300 for prostate cancer cell growth, which is maintained in the context of resistance to current therapy. In order to take therapeutic advantage of this vulnerability, we have developed a novel small-molecule inhibitor of the CBP/P300 bromodomain that blocks prostate cancer growth in vitro and in vivo. Molecular dissection of the consequences of drug treatment reveals a critical role for CBP/P300 in the histone acetylation required for AR transcriptional activity and target-gene expression. These findings strongly support CBP/P300 bromodomain inhibition as a therapeutic strategy in the treatment of castration resistant prostate cancer.
PubMed ID
No associated PubMed ID
Publication Title
No associated publication
Total Samples
Submitter’s Institution
No associated institution
No associated authors
Alternate Accession IDs


Show of 0 Total Samples
Accession Code
Processing Information
Additional Metadata
No rows found